Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Is (LH) Outperforming Other Medical Stocks This Year?

Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?

Artisan Partners Asset Management

General Motors

Hologic

Top Ranked Growth Stocks to Buy for November 17th

Camping World Hlds

II-VI Incorporated

Top Ranked Growth Stocks to Buy for November 13th

LabCorp is a mission-critical company that has been on the forefront of testing for COVID-19. I'm encouraged by the strong revenue backlog of its Covance drug development business, and by the secular growth trend of healthcare spend.

LabCorp: Making The Most Of Its Windfall Profits

Kroger

Snap-on

Molson Coors Brewing

Whirlpool

PEG-based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration.

5 Excellent PEG Stocks for GARP Investors

Laboratory Corporation Of America shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Laboratory Corp. Of America Profit Nearly Triples, Flashes Improved Price Strength appeared first on Investor's Business Daily.

Laboratory Corp. Of America Profit Nearly Triples, Flashes Improved Price Strength

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is LabCorp (LH) Stock Undervalued Right Now?

Co-Diagnostics

Fulgent Genetics

The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)

ATLAS CORP

Boise Cascade

Canadian Solar

Pampa Energia

Teva Pharmaceutical

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

6 Low Price-to-Book Value Stocks to Tap Market Boom

AGCO

Dollar General

Meritage Homes

Rush Enterprises

A company that is capable of generating earnings well above its interest expense can withstand financial hardships.

Scoop Up These 5 Stocks With Exciting Interest Coverage Ratio

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Hits 52-Week High, Can the Run Continue?

Gerdau

Sleep Number

Tempur Sealy International

Investing opportunistically in growth stocks is the way to go in volatile markets.

Investing in Growth Remains Solid Strategy: 4 Picks

QuidelOrtho Corp

Zai Lab Ltd.

The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio earlier this week.

Vanguard Health Care Fund Adds 3 Positions to Portfolio

In this article we will take a look at whether hedge funds think Laboratory Corp. of America Holdings (NYSE:LH) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Were Hedge Funds Right About Piling Into Laboratory Corp. of America Holdings (LH)?

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH) today announced that members of the executive management team will participate in a virtual fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, Nov. 9 at 8:00 a.m. ET. A live audio webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply

LabCorp Is Scheduled to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

Does LabCorp (LH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why LabCorp (LH) is a Great Choice

AmerisourceBergen

Align Technology

Becton, Dickinson and Co.

Cardinal Health

Cooper Companies

Henry Schein

McKesson

Patterson Companies

West Pharmaceutical Services

DENTSPLY SIRONA

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

On Wednesday, Laboratory Corporation Of America got an upgrade for its IBD SmartSelect Composite Rating from 92 to 98. The post LabCorp Earns Membership In 95-Plus Composite Rating Club appeared first on Investor's Business Daily.

LabCorp Earns Membership In 95-Plus Composite Rating Club

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2020 Results - Earnings Call Transcript

LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.

LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand

LabCorp (LH) delivered earnings and revenue surprises of 58.98% and 4.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Beats Q3 Earnings and Revenue Estimates

Shares of Laboratory Corp (NYSE:LH) moved higher by 0.5% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 190.00% over the past year to $8.41, which beat the estimate of $5.25.

Recap: Laboratory Corp Q3 Earnings

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (or the Company) (NYSE: LH) today announced results for the third quarter ended September 30, 2020. “LabCorp remains committed to fighting the pandemic through innovations in testing and clinical trials aimed at discovering treatments and vaccines. This combined with the dedication from our employees, advances our goal of improving health and improving lives. We delivered strong results in the quarter, with growth across both our Diagnostics and Drug D

LabCorp Announces 2020 Third Quarter Results

Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.

LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service

LabCorp (LH) closed the most recent trading day at $203.16, moving -1% from the previous trading session.

News for Labcorp Holdings Inc Stock (LH)